Bayer Brushes Off Xarelto Study Device Defect Worries
This article was originally published in Scrip
Bayer AG said it believes top-selling drug Xarelto (rivaroxaban) "remains a reasonable alternative to warfarin" despite worries a defective blood-clotting test device affected a key trial studying the novel anti-blood clotting pill used to underpin its approval for treating patients with irregular heartbeat.
You may also be interested in...
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.
Sanofi is paying for $3.68bn cash for Principia to get the US biotech’s drug development platform and nascent pipeline, including a brain-penetrant BTK inhibitor in Phase III for multiple sclerosis.